Baxter's nvestigational 20% subcutaneous immunoglobulin treatment meets efficacy endpoint
Baxter presented results of a Phase 2/3 study of its investigational 20 percent concentration subcutaneous immunoglobulin treatment for primary immunodeficiencies. The study met its primary endpoint that measured the rate of validated acute serious bacterial infections. October 30, 2014